# Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)

Study · id `cardio:ct-nct06359782` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06359782](<https://clinicaltrials.gov/study/NCT06359782>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06359782

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 128 participants.

## Technical summary

Registry record NCT06359782. Randomized; quadruple masking; primary purpose treatment. Start 2024-11-04 (actual); primary completion 2027-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 128 participants (planned count; ClinicalTrials.gov record NCT06359782, source copy `cardio:ctgov-nct06359782-2024-12-27`, retrieved 2026-10-31)
- Started: 2024-11-04 (actual) (ClinicalTrials.gov record NCT06359782, source copy `cardio:ctgov-nct06359782-2024-12-27`, retrieved 2026-10-31)
- Primary completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT06359782, source copy `cardio:ctgov-nct06359782-2024-12-27`, retrieved 2026-10-31)
- Completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT06359782, source copy `cardio:ctgov-nct06359782-2024-12-27`, retrieved 2026-10-31)
- Countries: Netherlands (ClinicalTrials.gov record NCT06359782, source copy `cardio:ctgov-nct06359782-2024-12-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06359782-2024-12-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)
- Acronym: CIAO@SAH
- Condition: Subarachnoid Hemorrhage, Aneurysmal
- Intervention (Drug): C1 Esterase Inhibitor Injection \[Cinryze\]
- Intervention (Drug): Placebo
- Lead sponsor: Haaglanden Medical Centre
- Lead sponsor class: OTHER
- Collaborator: Leiden University Medical Center
- Collaborator class: OTHER
- Collaborator: Takeda
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Subarachnoid hemorrhage (`cardio:subarachnoid-hemorrhage`)
- Registry lists this organization as a collaborator: Leiden University Medical Center (`cardio:org-leiden-university-medical-center`)
- Registry lists this organization as a collaborator: Takeda (`cardio:org-takeda`)

## Provenance

Content hash: c5f66b7464caae85256d520c83ad1f32f8be2dab799cf685d44335d9d31ec23f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
